

Lars Wallentin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7361887/publications.pdf>

Version: 2024-02-01

254
papers

44,299
citations

10986

71
h-index

1980

206
g-index

264
all docs

264
docs citations

264
times ranked

29627
citing authors

#	ARTICLE	IF	CITATIONS
1	Methodology for the development of international clinical data standards for common cardiovascular conditions: European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart). <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2023, 9, 161-168.	4.0	20
2	European Society of Cardiology methodology for the development of quality indicators for the quantification of cardiovascular care and outcomes. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 4-13.	4.0	52
3	Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease. <i>Cardiovascular Research</i> , 2022, 118, 295-304.	3.8	8
4	Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy. <i>Platelets</i> , 2022, 33, 425-431.	2.3	9
5	Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. <i>Cardiovascular Research</i> , 2022, 118, 2112-2123.	3.8	18
6	Diabetes status modifies the long-term effect of lipoprotein-associated phospholipase A2 on major coronary events. <i>Diabetologia</i> , 2022, 65, 101-112.	6.3	5
7	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 227-235.	3.0	6
8	Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. <i>Circulation</i> , 2022, 145, 242-255.	1.6	118
9	Body Mass Index and Association With Cardiovascular Outcomes in Patients With Stable Coronary Heart Disease – A STABILITY Substudy. <i>Journal of the American Heart Association</i> , 2022, 11, e023667.	3.7	19
10	Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATElet inhibition and patients Outcomes (PLATO) trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2022, 11, 336-349.	1.0	2
11	Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart). <i>European Heart Journal</i> , 2022, 43, 2185-2195.	2.2	12
12	Do we need to reconsider how we design and conduct randomised controlled trials?. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, , .	4.0	3
13	Genetic Landscape of the ACE2 Coronavirus Receptor. <i>Circulation</i> , 2022, 145, 1398-1411.	1.6	20
14	Data standards for acute coronary syndrome and percutaneous coronary intervention: the European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart). <i>European Heart Journal</i> , 2022, 43, 2269-2285.	2.2	7
15	Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model. <i>American Heart Journal</i> , 2022, 251, 13-24.	2.7	6
16	Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 549-559.	2.6	6
17	Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale. <i>American Heart Journal</i> , 2021, 233, 48-58.	2.7	11
18	Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline. <i>Kidney International</i> , 2021, 99, 926-939.	5.2	42

#	ARTICLE	IF	CITATIONS
19	Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 153-163.	1.0	12
20	Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study. <i>PLoS Medicine</i> , 2021, 18, e1003513.	8.4	70
21	Risk markers of incident atrial fibrillation in patients with coronary heart disease. <i>American Heart Journal</i> , 2021, 233, 92-101.	2.7	7
22	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. <i>European Heart Journal</i> , 2021, 42, 1742-1756.	2.2	63
23	Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. <i>Open Heart</i> , 2021, 8, e001471.	2.3	7
24	Excessive daytime sleepiness, morning tiredness and major adverse cardiovascular events in patients with chronic coronary syndrome. <i>Journal of Internal Medicine</i> , 2021, 290, 392-403.	6.0	8
25	The SWEDHEART secondary prevention and cardiac rehabilitation registry (SWEDHEART CR registry). <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 431-437.	4.0	15
26	Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). <i>American Journal of Cardiology</i> , 2021, 149, 27-35.	1.6	11
27	Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2726-2737.	3.8	17
28	Natriuretic peptides and incident atrial fibrillation. <i>American Heart Journal</i> , 2021, 241, 120.	2.7	0
29	Temporal changes of biomarkers in myocardial infarction patients with non-obstructive compared to obstructive coronary arteries. <i>European Heart Journal</i> , 2021, 42, .	2.2	0
30	Temporal trends in bleeding events in acute myocardial infarction: insights from the SWEDHEART registry. <i>European Heart Journal</i> , 2020, 41, 833-843.	2.2	53
31	Effects of apixaban compared with warfarin as gain in event-free time â€“ a novel assessment of the results of the ARISTOTLE trial. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1311-1319.	1.8	4
32	Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial. <i>Circulation</i> , 2020, 141, 10-20.	1.6	24
33	ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial. <i>Atherosclerosis</i> , 2020, 293, 35-41.	0.8	5
34	Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. <i>European Heart Journal</i> , 2020, 41, 4037-4046.	2.2	90
35	Extracellular vesicles in atrial fibrillation and stroke. <i>Thrombosis Research</i> , 2020, 193, 180-189.	1.7	15
36	Evaluation of the Age, Biomarkers, and Clinical Historyâ€“Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. <i>JAMA Network Open</i> , 2020, 3, e2015943.	5.9	5

#	ARTICLE	IF	CITATIONS
37	Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. <i>European Heart Journal</i> , 2020, 41, 2848-2859.	2.2	25
38	Comparative Efficacy and Safety of Oral P2Y ₁₂ Inhibitors in Acute Coronary Syndrome. <i>Circulation</i> , 2020, 142, 150-160.	1.6	93
39	Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2287-2295.	3.8	14
40	Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1145-1155.	2.8	28
41	Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis. <i>Europace</i> , 2020, 22, 870-877.	1.7	13
42	Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. <i>Circulation</i> , 2020, 141, 1384-1392.	1.6	87
43	Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. <i>Journal of the American College of Cardiology</i> , 2020, 76, 162-171.	2.8	50
44	Meta-Analysis of Intraocular Bleeding With Dual Antiplatelet Therapy Using P2Y ₁₂ Inhibitors Prasugrel or Ticagrelor. <i>American Journal of Cardiology</i> , 2020, 125, 1280-1283.	1.6	1
45	Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study. <i>PLoS ONE</i> , 2020, 15, e0226259.	2.5	1
46	Understanding the use of observational and randomized data in cardiovascular medicine. <i>European Heart Journal</i> , 2020, 41, 2571-2578.	2.2	24
47	Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial. <i>Journal of Internal Medicine</i> , 2020, 288, 248-259.	6.0	3
48	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1424-1437.	7.1	36
49	In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels ≤ 70 mg/dL and glycosylated hemoglobin A1c $\leq 7\%$ are associated with lower major cardiovascular events. <i>American Heart Journal</i> , 2020, 225, 97-107.	2.7	5
50	Cardiovascular Medicine in Sweden. <i>Circulation</i> , 2020, 141, 1124-1126.	1.6	5
51	Impaired Fibrinolysis Predicts Adverse Outcome in Acute Coronary Syndrome Patients with Diabetes: A PLATO Sub-Study. <i>Thrombosis and Haemostasis</i> , 2020, 120, 412-422.	3.4	27
52	Associations between psychosocial burden and prognostic biomarkers in patients with stable coronary heart disease – a STABILITY substudy. <i>European Heart Journal</i> , 2020, 41, .	2.2	0
53	Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATElet inhibition and patient Outcomes (PLATO) study. <i>Platelets</i> , 2019, 30, 579-588.	2.3	4
54	Interleukin-18 in patients with acute coronary syndromes. <i>Clinical Cardiology</i> , 2019, 42, 1202-1209.	1.8	16

#	ARTICLE	IF	CITATIONS
55	From Early Pharmacology to Recent Pharmacology Interventions in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1618-1636.	2.8	33
56	Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 563-569.	2.1	11
57	EuroHeart: European Unified Registries On Heart Care Evaluation and Randomized Trials. <i>European Heart Journal</i> , 2019, 40, 2745-2749.	2.2	56
58	A catalog of genetic loci associated with kidney function from analyses of a million individuals. <i>Nature Genetics</i> , 2019, 51, 957-972.	21.4	549
59	Ticagrelor in patients with heart failure after acute coronary syndromes—Insights from the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2019, 213, 57-65.	2.7	7
60	Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial. <i>Clinical Cardiology</i> , 2019, 42, 568-571.	1.8	80
61	Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution. <i>Nature Genetics</i> , 2019, 51, 452-469.	21.4	89
62	P4752 Apixaban 2.5 mg twice daily is effective and safe for patients with atrial fibrillation and combinations of advanced age, low body weight, and elevated creatinine: insights from ARISTOTLE. <i>European Heart Journal</i> , 2019, 40, .	2.2	0
63	P4747 Impact of different estimates of renal function on cardiovascular mortality and major bleeding in patients with atrial fibrillation on oral anticoagulation. <i>European Heart Journal</i> , 2019, 40, .	2.2	0
64	Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation. <i>Heart</i> , 2019, 105, 235-242.	2.9	19
65	Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. <i>Circulation</i> , 2019, 139, 863-873.	1.6	18
66	Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial. <i>American Heart Journal</i> , 2019, 208, 65-73.	2.7	14
67	Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. <i>American Heart Journal</i> , 2019, 208, 123-131.	2.7	54
68	Admission Levels of DKK1 (Dickkopf-1) Are Associated With Future Cardiovascular Death in Patients With Acute Coronary Syndromes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 294-302.	2.4	20
69	Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, G372-G386.	3.4	5
70	Bivalirudin versus heparin monotherapy in non-ST-segment elevation myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 492-501.	1.0	8
71	Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. <i>European Heart Journal</i> , 2018, 39, 1672-1686f.	2.2	106
72	Digoxin and Mortality in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1063-1074.	2.8	147

#	ARTICLE	IF	CITATIONS
73	Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 427-429.	3.4	1
74	Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 75-81.	3.0	9
75	Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. <i>European Heart Journal</i> , 2018, 39, 1078-1085.	2.2	109
76	A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, Tj ETQq0 0 0 rgBT /Oygrlock 10 Tf 50 622	2.2	92
77	Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient) Tj ETQq1 1 0.784314 rgBT /Overl	2.2	14
78	Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time – A RE-LY trial analysis. <i>American Heart Journal</i> , 2018, 198, 169-177.	2.7	14
79	Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 36-45.	3.0	14
80	Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial. <i>Journal of Internal Medicine</i> , 2018, 283, 282-292.	6.0	25
81	Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease. <i>Journal of Internal Medicine</i> , 2018, 283, 83-92.	6.0	57
82	P4797 Novel prognostic biomarkers identified by proximity extension assay are associated with major bleeding in patients with atrial fibrillation on oral anticoagulation: insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2018, 39, .	2.2	1
83	P625 Screening multiple biomarkers for associations with major coronary events. <i>European Heart Journal</i> , 2018, 39, .	2.2	0
84	P976 Elevated biomarkers are associated with increased risk of death and heart failure hospitalization in patients with atrial fibrillation: insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2018, 39, .	2.2	0
85	P6249 Screening multiple biomarkers for associations with acute ischemic stroke in patients with stable coronary heart disease. <i>European Heart Journal</i> , 2018, 39, .	2.2	0
86	2170 Screening multiple biomarkers for associations with cardiovascular death in patients with stable coronary heart disease. <i>European Heart Journal</i> , 2018, 39, .	2.2	0
87	Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2018, 3, 1160.	6.1	57
88	Lp-PLA2, scavenger receptor class B type I gene (SCARB1) rs10846744 variant, and cardiovascular disease. <i>PLoS ONE</i> , 2018, 13, e0204352.	2.5	2
89	Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014. <i>European Heart Journal</i> , 2018, 39, 3766-3776.	2.2	112
90	Natriuretic peptide should be used as a routine tool for evaluation of patients with atrial fibrillation. <i>Heart</i> , 2018, 105, heartjnl-2018-314040.	2.9	6

#	ARTICLE	IF	CITATIONS
91	Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 721-733.	2.8	31
92	Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 72, 37-43.	1.4	10
93	Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 255-267.	2.8	56
94	Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.7	4
95	Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome. <i>American Heart Journal</i> , 2018, 201, 25-32.	2.7	9
96	Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 856-864.	2.9	25
97	Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. <i>Circulation</i> , 2018, 138, 1666-1676.	1.6	34
98	Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. <i>Nature Genetics</i> , 2018, 50, 26-41.	21.4	286
99	Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. <i>European Heart Journal</i> , 2017, 38, ehw525.	2.2	164
100	Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 155-163.	1.0	1
101	Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy. <i>European Heart Journal: Acute Cardiovascular Care</i> . 2017, 6, 500-510.	1.0	17
102	Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. <i>American Heart Journal</i> , 2017, 186, 91-99.	2.7	36
103	Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome. <i>Clinical Chemistry</i> , 2017, 63, 573-584.	3.2	26
104	Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes After Treatment With Ticagrelor. <i>American Journal of Cardiology</i> , 2017, 119, 1135-1140.	1.6	5
105	Effects of dabigatran according to age in atrial fibrillation. <i>Heart</i> , 2017, 103, 1015-1023.	2.9	78
106	Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. <i>Lancet, The</i> , 2017, 389, 1025-1034.	13.7	840
107	Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	27
108	Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 145-153.	2.1	18

#	ARTICLE	IF	CITATIONS
109	Relative efficacy and safety of ticagrelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial. <i>Clinical Cardiology</i> , 2017, 40, 390-398.	1.8	16
110	Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. <i>American Heart Journal</i> , 2017, 190, 94-103.	2.7	42
111	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 534-543.	11.4	84
112	Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors. <i>European Heart Journal</i> , 2017, 38, 1048-1055.	2.2	44
113	Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. <i>American Heart Journal</i> , 2017, 187, 194-203.	2.7	26
114	Potent P2Y ₁₂ Inhibitors in Men Versus Women. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1549-1559.	2.8	51
115	Application of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation. <i>Clinical Chemistry</i> , 2017, 63, 152-164.	3.2	79
116	Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease. <i>Clinical Chemistry</i> , 2017, 63, 140-151.	3.2	380
117	Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. <i>Clinical Chemistry</i> , 2017, 63, 325-333.	3.2	97
118	Inflammatory Biomarkers Interleukin-6 and C-reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of) Trial. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1689-1700.	2.8	186
119	Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin. <i>Stroke</i> , 2017, 48, 3266-3273.	2.0	20
120	Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1689-1700.	2.8	186
121	Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by) Trial. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1689-1700.	2.8	186
122	Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. <i>New England Journal of Medicine</i> , 2017, 377, 1132-1142.	27.0	228
123	Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014. <i>European Heart Journal</i> , 2017, 38, 3056-3065.	2.2	302
124	Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	8
125	Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial. <i>Open Heart</i> , 2017, 4, e000557.	2.3	4
126	Unreliable Observations from a Confounded Analysis of a Skewed Database. <i>American Journal of Medicine</i> , 2017, 130, e355-e356.	1.5	0

#	ARTICLE	IF	CITATIONS
127	Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease. <i>International Journal of Cardiology</i> , 2017, 245, 271-276.	1.7	22
128	Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2017, 70, 813-826.	2.8	95
129	Antibodies against MYC-Associated Zinc Finger Protein: An Independent Marker in Acute Coronary Syndrome?. <i>Frontiers in Immunology</i> , 2017, 8, 1595.	4.8	5
130	Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib. <i>PLoS ONE</i> , 2017, 12, e0182115.	2.5	16
131	Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial. <i>European Heart Journal</i> , 2017, 38, 2813-2822.	2.2	45
132	P3626 Serial IL-6 levels and risk of death in anticoagulated patients with atrial fibrillation: Insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2017, 38, .	2.2	0
133	Commentary on the OPTIDUAL trial results: how to optimise prolonged dual antiplatelet treatment and independent randomised clinical trials. <i>European Heart Journal</i> , 2016, 37, ehv499.	2.2	5
134	D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy. <i>Thrombosis and Haemostasis</i> , 2016, 115, 921-930.	3.4	34
135	Renal Function in Atrial Fibrillation. <i>Circulation</i> , 2016, 134, 48-51.	1.6	13
136	Exome Genotyping Identifies Pleiotropic Variants Associated with Red Blood Cell Traits. <i>American Journal of Human Genetics</i> , 2016, 99, 8-21.	6.2	60
137	All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome. <i>Heart</i> , 2016, 102, 926-933.	2.9	70
138	The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. <i>Lancet</i> , The, 2016, 387, 2302-2311.	13.7	389
139	Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 5-12.	3.0	40
140	Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial. <i>American Heart Journal</i> , 2016, 178, 1-8.	2.7	15
141	Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2135-2144.	2.8	66
142	Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease. <i>European Heart Journal</i> , 2016, 37, 1993-2001.	2.2	101
143	Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>American Heart Journal</i> , 2016, 177, 1-8.	2.7	23
144	Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. <i>American Heart Journal</i> , 2016, 178, 176-184.	2.7	5

#	ARTICLE	IF	CITATIONS
145	Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. <i>Lancet, The</i> , 2016, 388, 1161-1169.	13.7	216
146	Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. <i>Pharmacogenomics</i> , 2016, 17, 1425-1439.	1.3	21
147	Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. <i>Circulation</i> , 2016, 134, 1697-1707.	1.6	76
148	Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study. <i>Lancet, The</i> , 2016, 388, 1903-1911.	13.7	68
149	Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. <i>European Heart Journal</i> , 2016, 37, 3335-3342.	2.2	138
150	The ABC risk score for patients with atrial fibrillation – Authors' reply. <i>Lancet, The</i> , 2016, 388, 1980-1981.	13.7	3
151	Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. <i>BMJ, The</i> , 2016, 353, i2868.	6.0	123
152	Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals. <i>American Journal of Human Genetics</i> , 2016, 99, 40-55.	6.2	82
153	Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time. <i>JAMA Cardiology</i> , 2016, 1, 451.	6.1	137
154	Lipoprotein-associated Phospholipase A ₂ Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	44
155	Large-Scale Exome-wide Association Analysis Identifies Loci for White Blood Cell Traits and Pleiotropy with Immune-Mediated Diseases. <i>American Journal of Human Genetics</i> , 2016, 99, 22-39.	6.2	50
156	Evaluation of Temporal Changes in Cardiovascular Biomarker Concentrations Improves Risk Prediction in an Elderly Population from the Community. <i>Clinical Chemistry</i> , 2016, 62, 485-493.	3.2	17
157	Tooth loss is independently associated with poor outcomes in stable coronary heart disease. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 839-846.	1.8	39
158	Dabigatran etexilate and reduction in serum apolipoprotein B. <i>Heart</i> , 2016, 102, 57-62.	2.9	34
159	Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2016, 1, 73.	6.1	22
160	Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial. <i>Thrombosis Research</i> , 2016, 139, 77-81.	1.7	29
161	Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. <i>Heart</i> , 2016, 102, 617-625.	2.9	56
162	Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. <i>Heart</i> , 2016, 102, 508-517.	2.9	67

#	ARTICLE	IF	CITATIONS
163	History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. American Heart Journal, 2016, 175, 175-183.	2.7	16
164	Bivalirudin versus heparin in non-ST and ST-segment elevation myocardial infarction—a registry-based randomized clinical trial in the SWEDEHEART registry (the VALIDATE-SWEDEHEART trial). American Heart Journal, 2016, 175, 36-46.	2.7	31
165	Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events. Thrombosis Research, 2016, 140, 81-88.	1.7	14
166	The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. European Heart Journal, 2016, 37, 1582-1590.	2.2	329
167	Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. Europace, 2016, 18, 973-978.	1.7	19
168	Chronic obstructive pulmonary disease in patients with atrial fibrillation: Insights from the ARISTOTLE trial. International Journal of Cardiology, 2016, 202, 589-594.	1.7	38
169	Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. European Heart Journal, 2016, 37, 1325-1333.	2.2	137
170	Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 86-94.	3.0	59
171	Comparison of hospital variation in acute myocardial infarction care and outcome between Sweden and United Kingdom: population based cohort study using nationwide clinical registries. BMJ, The, 2015, 351, h3913.	6.0	94
172	Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery. Journal of the American Heart Association, 2015, 4, .	3.7	8
173	Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. European Heart Journal, 2015, 36, 1901-1912.	2.2	107
174	Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American Heart Journal, 2015, 169, 899-905.e1.	2.7	91
175	Magnitude of Troponin Elevation and Long-Term Clinical Outcomes in Acute Coronary Syndrome Patients Treated With and Without Revascularization. Circulation: Cardiovascular Interventions, 2015, 8, e002314.	3.9	22
176	Therapeutic Hypothermia for the Treatment of Acute Myocardial Infarction—Combined Analysis of the RAPID MI-ICE and the CHILL-MI Trials. Therapeutic Hypothermia and Temperature Management, 2015, 5, 77-84.	0.9	54
177	Changes in Renal Function in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2015, 65, 2481-2493.	2.8	197
178	Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Journal of the American Heart Association, 2015, 4, .	3.7	68
179	Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. European Heart Journal, 2015, 36, ehv447.	2.2	35
180	Economic Analysis of Ticagrelor Therapy From a U.S. Perspective. Journal of the American College of Cardiology, 2015, 65, 465-476.	2.8	30

#	ARTICLE	IF	CITATIONS
181	Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APIxaban for PRevention of Acute ISchemic Events 2 trial. American Heart Journal, 2015, 169, 531-538.	2.7	9
182	Association Between the Use of Fondaparinux vs Low-Molecular-Weight Heparin and Clinical Outcomes in Patients With Nonâ€“ST-Segment Elevation Myocardial Infarction. JAMA - Journal of the American Medical Association, 2015, 313, 707.	7.4	31
183	Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation: An ARISTOTLE Substudy. Clinical Chemistry, 2015, 61, 368-378.	3.2	37
184	Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy. Heart, 2015, 101, 119-125.	2.9	15
185	Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. European Heart Journal, 2015, 36, ehv304.	2.2	175
186	Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Journal of the American Heart Association, 2015, 4, e002490.	3.7	37
187	Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial. American Heart Journal, 2015, 169, 879-889.e7.	2.7	42
188	Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. American Heart Journal, 2015, 170, 1151-1160.	2.7	99
189	Metaâ€“Analysis of Intracranial Hemorrhage in Acute Coronary Syndromes: Incidence, Predictors, and Clinical Outcomes. Journal of the American Heart Association, 2015, 4, e001512.	3.7	19
190	Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. European Heart Journal, 2015, 36, 1264-1272.	2.2	144
191	Periodontal disease in patients with chronic coronary heart disease: Prevalence and association with cardiovascular risk factors. European Journal of Preventive Cardiology, 2015, 22, 771-778.	1.8	41
192	Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. European Journal of Preventive Cardiology, 2015, 22, 734-742.	1.8	82
193	Response to Letter Regarding Article, â€“Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized) Tj ETQq1 1 0.784314 108 /Overlock 10 T		
194	Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. European Heart Journal, 2014, 35, 1864-1872.	2.2	303
195	Response to Letter Regarding Article, â€“Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillationâ€“. Circulation, 2014, 129, e21-2.	1.6	1
196	Response to Letter Regarding Article, â€“Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarinâ€“. Circulation, 2014, 130, e95.	1.6	0
197	Vorapaxar with or without clopidogrel after nonâ€“ST-segment elevation acute coronary syndromes: Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial. American Heart Journal, 2014, 168, 869-877.e1.	2.7	21
198	Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER. Journal of the American Heart Association, 2014, 3, .	3.7	9

#	ARTICLE	IF	CITATIONS
199	The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients. <i>Journal of the American College of Cardiology</i> , 2014, 63, 321-328.	2.8	733
200	Prognostic Usefulness of Left Ventricular Hypertrophy by Electrocardiography in Patients With Atrial Fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). <i>American Journal of Cardiology</i> , 2014, 113, 669-675.	1.6	14
201	Acute myocardial infarction: a comparison of short-term survival in national outcome registries in Sweden and the UK. <i>Lancet</i> , The, 2014, 383, 1305-1312.	13.7	258
202	Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non- σ ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization. <i>Circulation</i> , 2014, 129, 293-303.	1.6	100
203	Association of cyclooxygenase-2 genetic variant with cardiovascular disease. <i>European Heart Journal</i> , 2014, 35, 2242-2248.	2.2	42
204	Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease. <i>New England Journal of Medicine</i> , 2014, 370, 1702-1711.	27.0	467
205	Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries. <i>Circulation</i> , 2014, 129, 1568-1576.	1.6	324
206	Rapid Endovascular Catheter Core Cooling Combined With Cold Saline as an Adjunct to Percutaneous Coronary Intervention for the Treatment of Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1857-1865.	2.8	203
207	Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2014, 168, 68-75.e2.	2.7	18
208	Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. <i>European Heart Journal</i> , 2014, 35, 2083-2093.	2.2	171
209	The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATElet inhibition and patient Outcomes (PLATO) trial. <i>European Heart Journal</i> , 2014, 35, 1541-1550.	2.2	70
210	Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome. <i>International Journal of Cardiology</i> , 2014, 170, e59-e62.	1.7	10
211	High-Sensitivity Troponin T and Risk Stratification in Patients With Atrial Fibrillation During Treatment With Apixaban or Warfarin. <i>Journal of the American College of Cardiology</i> , 2014, 63, 52-61.	2.8	133
212	Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients With Atrial Fibrillation. <i>Circulation</i> , 2014, 130, 1847-1858.	1.6	243
213	Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. <i>Heart</i> , 2014, 100, 1762-1769.	2.9	38
214	How can we optimize the processes of care for acute coronary syndromes to improve outcomes?. <i>American Heart Journal</i> , 2014, 168, 622-631.e2.	2.7	16
215	Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy. <i>Heart</i> , 2014, 100, 1193-1200.	2.9	47
216	Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2014, 3, 246-256.	1.0	13

#	ARTICLE	IF	CITATIONS
217	No misrepresentation of vital status follow-up in PLATO: Predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial. <i>International Journal of Cardiology</i> , 2014, 176, 300-302.	1.7	4
218	Usefulness and Safety of Vorapaxar in Patients With Non-“ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (from the TRACER Trial). <i>American Journal of Cardiology</i> , 2014, 114, 665-673.	1.6	17
219	Amiodarone, Anticoagulation, and Clinical Events in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1541-1550.	2.8	84
220	Antiplatelet and anticoagulation agents in acute coronary syndromes: What is the current status and what does the future hold?. <i>American Heart Journal</i> , 2014, 168, 611-621.	2.7	34
221	Ticagrelor Effects on Myocardial Infarction and the Impact of Event Adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) Trial. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1493-1499.	2.8	47
222	Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1048-1057.	2.8	40
223	Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Non-“ST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial). <i>American Journal of Cardiology</i> , 2014, 113, 936-944.	1.6	17
224	Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATElet inhibition and patient Outcomes study. <i>American Heart Journal</i> , 2014, 168, 96-102.e2.	2.7	17
225	Angiographic Outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 671-683.	2.9	35
226	Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 678-685.	1.8	60
227	Biomarkers in atrial fibrillation: a clinical review. <i>European Heart Journal</i> , 2013, 34, 1475-1480.	2.2	246
228	N-Terminal Pro-B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2274-2284.	2.8	191
229	Difference in causes of death between ticagrelor and clopidogrel in the PLATO trial. <i>European Heart Journal</i> , 2013, 34, 4536-4536.	2.2	0
230	Reduction in recurrent ischemic events with vorapaxar: results from TRACER. <i>European Heart Journal</i> , 2013, 34, P4842-P4842.	2.2	0
231	GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men. <i>PLoS ONE</i> , 2013, 8, e78797.	2.5	108
232	Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation. <i>Circulation</i> , 2012, 125, 1605-1616.	1.6	346
233	Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial: reply to a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 502-504.	3.8	1
234	Apixaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 981-992.	27.0	7,537

#	ARTICLE	IF	CITATIONS
235	ProteinSeq: High-Performance Proteomic Analyses by Proximity Ligation and Next Generation Sequencing. PLoS ONE, 2011, 6, e25583.	2.5	80
236	Association Between Adoption of Evidence-Based Treatment and Survival for Patients With ST-Elevation Myocardial Infarction. JAMA - Journal of the American Medical Association, 2011, 305, 1677.	7.4	356
237	Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurology, The, 2010, 9, 1157-1163.	10.2	399
238	Apixaban for Reduction In Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale. American Heart Journal, 2010, 159, 331-339.	2.7	407
239	ST2 and mortality in non-ST-segment elevation acute coronary syndrome. American Heart Journal, 2010, 159, 788-794.	2.7	71
240	Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 547 T patients with coronary heart disease. American Heart Journal, 2010, 160, 655-661.e2.	2.7	111
241	The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART). Heart, 2010, 96, 1617-1621.	2.9	537
242	Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. American Heart Journal, 2009, 157, 805-810.e2.	2.7	298
243	Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine, 2009, 361, 1045-1057.	27.0	6,019
244	Dabigatran versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2009, 361, 1139-1151.	27.0	9,839
245	Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATElet inhibition and patient Outcomes (PLATO) trial. American Heart Journal, 2009, 157, 599-605.	2.7	363
246	Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. European Heart Journal, 2007, 29, 21-30.	2.2	408
247	Long-Term Outcomes with Drug-Eluting Stents versus Bare-Metal Stents in Sweden. New England Journal of Medicine, 2007, 356, 1009-1019.	27.0	1,113
248	5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study. Lancet, The, 2006, 368, 998-1004.	13.7	242
249	Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes. New England Journal of Medicine, 2006, 354, 1464-1476.	27.0	1,104
250	The Cardiology Audit and Registration Data Standards (CARDS), European data standards for clinical cardiology practice. European Heart Journal, 2005, 26, 308-313.	2.2	132
251	Outcome of ST-elevation myocardial infarction treated with thrombolysis in the unselected population is vastly different from samples of eligible patients in a large-scale clinical trial. American Heart Journal, 2004, 148, 566-573.	2.7	50
252	New Generation Cardiac Troponin I Assay for the Access Immunoassay System. Clinical Chemistry, 2001, 47, 959-961.	3.2	40

#	ARTICLE	IF	CITATIONS
253	Lecithin: Cholesterol Acyl Transfer Rate in Plasma and its Relations to Lipoprotein Concentrations and to Kinetics of Bile Acids and Triglycerides in Hyperlipoproteinemic Subjects. Scandinavian Journal of Clinical and Laboratory Investigation, 1978, 38, 103-110.	1.2	9
254	Serum Neurofilament Light Chain in Patients With Atrial Fibrillation. Journal of the American Heart Association, 0, , .	3.7	7